HAE250117P80000
- 5.30
- -0.30-5.36%
Haemonetics Newsroom
Earnings Grew Faster Than the Favorable 12% CAGR Delivered to Haemonetics (NYSE:HAE) Shareholders Over the Last Three Years
Down -11.82% in 4 Weeks, Here's Why You Should You Buy the Dip in Haemonetics (HAE)
Haemonetics: Strong Market Position and Attractive Investment Opportunity Amid Growth in Plasma and Hospital Segments
Should You Continue to Hold TMO Stock in Your Portfolio?
Are Investors Undervaluing Haemonetics (HAE) Right Now?
This Constellation Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts Offer Insights on Healthcare Companies: Haemonetics (HAE) and Terns Pharmaceuticals (TERN)
Express News | Haemonetics Corp : JP Morgan Initiates Coverage With Overweight Rating; Price Target $116
Haemonetics' Strategic Divestment to Boost Core Apheresis Focus and Long-term Growth
Barrington Maintains Haemonetics(HAE.US) With Buy Rating, Maintains Target Price $108
Haemonetics Corporation: Strategic Divestment and Innovation Drive Buy Rating With $125 Target
Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?
TMO Stock to Gain From the New Additions to CTS Portfolio of Products
Haemonetics Is Maintained at Outperform by Barrington Research
Wall Street Analysts See a 27.84% Upside in Haemonetics (HAE): Can the Stock Really Move This High?
Will HAE Stock Gain Following Sell-Off of Whole Blood Assets to GVS?
Reasons to Retain EYE Stock in Your Portfolio for Now
Needham Reiterates Buy on Haemonetics, Maintains $112 Price Target
Haemonetics to Sell Whole Blood Assets to GVS for $67.1 Million
Haemonetics: To Use Proceeds for General Corporate Purposes and Growth Initiatives>HAE